Cynosure (NASDAQ: CYNO) is one of 83 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare Cynosure to related businesses based on the strength of its institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Earnings & Valuation

This table compares Cynosure and its rivals revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Cynosure N/A N/A 101.49
Cynosure Competitors $2.06 billion $438.96 million -76.08

Cynosure’s rivals have higher revenue and earnings than Cynosure. Cynosure is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Cynosure and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cynosure 0.70% 0.75% 0.59%
Cynosure Competitors -327.91% -35.75% -12.50%

Analyst Ratings

This is a breakdown of recent recommendations for Cynosure and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cynosure 0 3 1 0 2.25
Cynosure Competitors 267 1850 3311 105 2.59

Cynosure presently has a consensus price target of $58.00, suggesting a potential downside of 12.08%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.71%. Given Cynosure’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Cynosure has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

51.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 2.9% of Cynosure shares are owned by insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Cynosure has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Cynosure’s rivals have a beta of 0.90, meaning that their average share price is 10% less volatile than the S&P 500.


Cynosure rivals beat Cynosure on 7 of the 11 factors compared.

About Cynosure

Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with's FREE daily email newsletter.